Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

E-Therapeutics launches research collaboration with Novo Nordisk

Mon, 10th Dec 2018 14:30

(Sharecast News) - E-Therapeutics announced a research collaboration with Novo Nordisk on Monday, under which the two companies would use e-Therapeutics' proprietary 'Network-Driven Drug Discovery' (NDD) platform to look to discover potentially novel biological mechanisms and therapeutic approaches for a specific area of type-2 diabetes.The AIM-traded firm said type-2 diabetes currently accounted for about 90% of the estimated 425 million people with diabetes worldwide, with new treatments urgently required to tackle the growing incidence of the condition.Under the agreement, e-Therapeutics would work with Novo Nordisk for a period of 12 months, and use its NDD approach to identify novel intervention strategies, biological pathways and compounds for testing that could potentially form the basis of novel therapies."We are looking forward to cooperating with e-therapeutics. It is an exciting technology and we will investigate if it can support some of the early target discovery efforts we are building in Novo Nordisk Research Center Oxford," said Jan Nygaard Jensen, head of bioinformatics at Novo Nordisk and deputy head of that company's research centre in Oxford.E-Therapeutics said it would be reimbursed for its work under the collaboration, with Novo Nordisk retaining the option to license relevant intellectual property generated under the collaboration.Any future license would require mutual agreement of commercial terms, with financial details of the collaboration not disclosed."We are delighted to be working with Novo Nordisk, a world leader and innovator in diabetes care," said e-Therapeutics chief executive officer Dr Ray Barlow."This collaboration highlights the use of our NDD platform to understand and potentially create new treatments for complex diseases of great relevance to society, medicine and the industry."Our new collaboration with Novo Nordisk is the result of a systematic and rigorous business development exercise over the past year and we hope to announce a number of additional collaborations during the course of 2019."
More News
8 May 2014 10:51

e-Therapeutics Trading Up As Brain Cancer Trial To Resume Recruitment

LONDON (Alliance News) - Shares in e-Therapeutics PLC were trading higher Thursday after it said that it had been cleared by the US Food and Drug administration to resume recruiting patients for its Phase Ia study of compound ETS2101 in brain cancer. The company had previously paused recrui

Read more
7 Apr 2014 12:25

UPDATE: e-Therapeutics Appoints Steve Medlicott Chief Financial Officer

LONDON (Alliance News) - e-Therapeutics PLC Monday said that it had appointed Steve Medlicott as Chief Financial Officer, following the resignation of Daniel Elger with immediate effect, also announced Monday. Medlicott had advised the company on its GBP40 million fund-raising in 2013. Medl

Read more
7 Apr 2014 10:57

e-Therapeutics's Chief Financial Officer Daniel Elger Resigns

LONDON (Alliance News) - e-Therapeutics PLC Monday said that Daniel Elger has resigned as Chief Financial officer and a director of the company, with immediate effect. e-Therapeutics said that the company's finances will be managed on an interim basis by Paul Stockdale, who has been the com

Read more
31 Mar 2014 12:50

REPEAT: UK MIDDAY BRIEFING: Babcock JV Wins GBP7 Billion Nuclear Contract

LONDON (Alliance News) - Babcock International Group is leading the FTSE 100 higher Monday after its Cavendish Fluor Partnership joint venture was selected as the preferred bidder for a GBP7 billion nuclear plant decommissioning contract.

The joint venture with Fluo

Read more
31 Mar 2014 12:45

UK MIDDAY BRIEFING: Babcock JV Wins GBP7 Billion Nuclear Contract

LONDON (Alliance News) - Babcock International Group is leading the FTSE 100 higher Monday after its Cavendish Fluor Partnership joint venture was selected as the preferred bidder for a GBP7 billion nuclear plant decommissioning contract.

The joint venture with Flou

Read more
31 Mar 2014 10:35

UK WINNERS & LOSERS: Babcock Leads FTSE 100 Risers; Insurers Rebound

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.

-------

FTSE 100 - WINNERS

Babcock International Group, up 3.5%. The company said its Cavendish Fluor Partnership has

Read more
31 Mar 2014 08:33

e-Therapeutics Rises As It Gets Good Interim Drug Trial Results

LONDON (Alliance News) - e-Therapeutics PLC Monday said it had achieved positive interim results from a UK study evaluating the safety, dosing and anti-tumour activity of its ETS2101 drug in patients with advanced solid cancer tumours. In a statement, the company said that it had completed

Read more
26 Mar 2014 13:40

UK MIDDAY BRIEFING: Government Completes 2nd Lloyds Bank Stake Sale

LONDON (Alliance News) - The UK government has raised a further GBP4.20 billion from its second sale of Lloyds Banking Group PLC shares, meaning it has now recouped GBP7.41 billion of the roughly GBP21 million that taxpayers injected into the bank during the financial crisis.<

Read more
26 Mar 2014 11:30

UK WINNERS & LOSERS: Standard Life Leads FTSE 100 Risers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.

-------

FTSE 100 - WINNERS

Standard Life, up 5.2%. The company has agreed to buy Ignis Asset Mana

Read more
26 Mar 2014 11:03

e-Therapeutics Gains As Recruitment For Cancer Trial Resumes

LONDON (Alliance News) - Shares in e-Therapeutics PLC jumped Wednesday morning after the biotechnology company said it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial. Recruitment for the trial was temporarily paused ov

Read more
24 Jan 2014 12:41

UK MIDDAY BRIEFING: Bank Of England Now Focused On Productivity

LONDON (Alliance News) - Bank of England Governor Mark Carney Friday signaled that rising productivity will now be the key factor that decides when the central bank will start to tighten monetary policy, and any tightening will be a slow, gradual process.

In a speech at the World Ec

Read more
24 Jan 2014 11:01

e-Therapeutics Temporarily Halts Recruitment In Trial Due To Drug Supply Issue

LONDON (Alliance News) - Shares in e-Therapeutics PLC dropped 16% Friday morning after it said that it was temporarily halting recruitment into its ETS2101 cancer trials due to a drug supply issue. e-Therapeutics said that there had been a practical issue with the stored drugs for the trial

Read more
24 Jan 2014 10:58

UK WINNERS & LOSERS: Cairn Falls As Indian Tax Department Gets In Touch

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Weir Group, up 0.2%. The engineering company said it had won a USD98 million, or GBP59 million, two-year contract to provide

Read more
7 Jan 2014 08:22

AIM IN BRIEF: H&T Says Profit As Expected, But Gold Price Has Hurt

Read more
31 Oct 2013 13:36

e-Therapeutics Starts Phase IIb Trial Of Depressive Disorder Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.